FDA approves anti-VEGF for treatment of branch, central retinal vein occlusion
Links shared publicly online about this topic.
- 1,073total visits
FDA approves anti-VEGF for treatment of branch, central retinal vein occlusion
SOUTH SAN FRANCISCO, Calif. " Following a 6-month priority review, the U.S. Food and Drug Administration has approved ranibizumab for treatment
View full resource at osnsupersite.com
Tags: Circulation, Diet and Nutrition, Drug, FDA, Ophthalmology, News
Most Recently Shared on June 24, 2010 at 12:35 am By:
RT @OSNSuperSite: #FDA approves anti-VEGF for treatment of branch, central retinal vein occlusion: http://ht.ly/22dYb ^@GrandRounds4ODs
Also Shared By:
Drug therapy for macular oedema treatment approved - Ophthalmology Times Europe
oteurope.com — “Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.” View full resource at oteurope.com
Most Recently Shared on June 25, 2009 at 1:32 pm By:
Ophthalmology Times Ophthalmology and Health Magazine
Drug therapy for macular oedema treatment approved. http://ow.ly/fOO4
Advertisement
The OSN SuperSite
@OSNSuperSite
#FDA approves anti-VEGF for treatment of branch, central retinal vein occlusion: http://ht.ly/22dYb — #Breaking #ophthalmology #news
1 year ago...